A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG: Lazertinib
DRUG: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
DRUG: Amivantamab Intravenous

Sponsor

Janssen Research & Development, LLC